Atypical teratoid rhabdoid tumor epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 15: Line 15:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Oncology]]
[[Category:Types of cancer]]
[[Category:Types of cancer]]
[[Category:Rare cancers]]
[[Category:Rare cancers]]

Revision as of 12:55, 17 August 2015

Atypical teratoid rhabdoid tumor Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Atypical Teratoid Rhabdoid Tumor from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Atypical teratoid rhabdoid tumor epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Atypical teratoid rhabdoid tumor epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Atypical teratoid rhabdoid tumor epidemiology and demographics

CDC on Atypical teratoid rhabdoid tumor epidemiology and demographics

Atypical teratoid rhabdoid tumor epidemiology and demographics in the news

Blogs on Atypical teratoid rhabdoid tumor epidemiology and demographics

Directions to Hospitals Treating Atypical teratoid rhabdoid tumor

Risk calculators and risk factors for Atypical teratoid rhabdoid tumor epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Epidemiology and Demographics

In the United States, three children per 1,000,000 or around 30 new AT/RT cases are diagnosed each year. AT/RT represents around 3% of pediatric cancers of the central nervous system (CNS).[1] Around 17% of all pediatric cancers involve the CNS; it is the most common childhood solid tumor. The survival rate for CNS tumors is around 60%; with AT/RT it is around 10%. Pediatric brain cancer is the second leading cause of childhood death, just after leukemia. Recent trends suggest that the rate of overall CNS tumor diagnosis is increasing by about 2.7% per year. As diagnostic techniques using genetic markers improve and are used more often, the proportion of AT/RT diagnoses is expected to increase.

Since it is highly malignant, AT/RT has a high mortality rate. A survey of 36 AT/RT patients at St. Jude Children's Hospital from 1984 to 2003 showed the survival rate for children under three is less than 10%, whereas for older children, the survival rate is potentially over 70%.[2] Because most patients with AT/RT are less than three years old, the overall prognosis for AT/RT is very poor.

An estimated 3% of pediatric brain tumors are AT/RTs although this percentage may increase with better differentiation between PNET/medulloblastoma tumors and AT/RTs. As with other CNS tumors, slightly more males are affected than females (ratio 1.6:1). The ASCO study showed a 1.4:1 male to female ratio.

References

  1. Measure D6: Types of Childhood Cancer – 2006 Tables D6a & D6b. U.S. Environmental Protection Agency. Retrieved on 2008-04-17.
  2. Tekautz TM, Fuller CE, Blaney S; et al. (2005). "Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy". J. Clin. Oncol. 23 (7): 1491–9. doi:10.1200/JCO.2005.05.187. PMID 15735125. See Figure 1.

Template:WH Template:WS